Immune Pharmaceuticals Inc., formerly EpiCept Corporation, is a specialty pharmaceutical company focused on the clinical development and commercialization of pharmaceutical products for the treatment of cancer and pain. It focuses on topically delivered analgesics targeting peripheral nerve receptors and on cancer therapies. Its oncology compounds include crolibulin and Azixa. Crolibulin is a small molecule vascular disruption agent (VDA) and apoptosis inducer for the treatment of patients with solid tumors. Azixa is licensed to Myrexis Inc. for clinical development. Azixa demonstrated a range of anti-tumor activities against many tumor types in various animal models. Ceplene, which when used concomitantly with low-dose interleukin-2 (IL-2) is intended as remission maintenance therapy in the treatment of acute myeloid leukemia (AML) for adult patients who are in their first complete remission. Effective August 26, 2013, Immune Pharmaceuticals Ltd merged with the Company.